

ERRATUM

S. aureus Infections in Chicago, 2006-2014: Increase in CA MSSA and Decrease in MRSA Incidence – ERRATUM

In the article by Acree, et al.¹, an error introduced during the production process resulted in the initial header for Table 3 incorrectly reading “MSSA Blood Isolates (n = 578).” The correct header should read “MRSA SSTI Isolates (n = 3,940).” The entire corrected table appears below. The publisher apologizes to the authors and readers for this error.

REFERENCE

1. Acree ME, Morgan E, David MZ. *S. aureus* Infections in Chicago, 2006-2014: Increase in CA MSSA and Decrease in MRSA Incidence. *Infection Control Hosp Epidemiol* 2017; 38:1226–1234.

TABLE 3. Susceptibility to Tested Antimicrobial Agents, MRSA and MSSA Isolates From SSTIs and Blood, Combining Pediatric and Adult Isolates, by Year, University of Chicago Medicine, 2006–2014

MRSA SSTI Isolates (n = 3,940)						
Year	Gentamicin ^a	Erythromycin	Rifampin	Tetracycline ^b	Ciprofloxacin ^b	Clindamycin ^b
	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)
2006	576 (100.0)	45 (7.8)	571 (99.1)	575 (99.8)	483 (83.9)	502 (87.2)
2007	543 (100.0)	41 (7.6)	543 (100.0)	542 (99.8)	448 (82.5)	451 (83.1)
2008	556 (100.0)	49 (8.8)	554 (99.6)	556 (100.0)	459 (82.6)	467 (84.0)
2009	476 (100.0)	37 (7.8)	473 (99.4)	475 (99.8)	360 (75.6)	386 (81.1)
2010	481 (100.0)	45 (9.4)	475 (98.8)	481 (100.0)	369 (76.7)	392 (81.5)
2011	423 (100.0)	41 (9.7)	422 (99.5)	414 (97.6)	352 (83.2)	332 (78.3)
2012	384 (100.0)	38 (9.9)	383 (99.7)	357 (93.0)	281 (73.2)	297 (77.3)
2013	400 (100.0)	40 (10.0)	398 (99.5)	386 (96.5)	286 (71.5)	317 (79.3)
2014, Q1	100 (100.0)	11 (11.0)	98 (98.0)	92 (92.0)	68 (68.0)	70 (70.0)

MSSA SSTI Isolates (n = 3,006)						
Year	Gentamicin ^a	Erythromycin	Rifampin	Tetracycline ^b	Ciprofloxacin	Clindamycin ^b
	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)
2006	348 (100.0)	239 (68.7)	346 (99.4)	348 (100.0)	334 (96.0)	332 (95.4)
2007	351 (100.0)	236 (67.2)	349 (99.4)	351 (100.0)	338 (96.3)	317 (90.3)
2008	322 (100.0)	205 (63.7)	322 (100.0)	322 (100.0)	301 (93.5)	252 (78.3)
2009	360 (100.0)	252 (70.0)	360 (100.0)	360 (100.0)	337 (93.6)	306 (85.0)
2010	383 (100.0)	255 (66.6)	383 (100.0)	383 (100.0)	359 (93.7)	310 (80.9)
2011	331 (100.0)	206 (62.2)	331 (100.0)	323 (97.6)	319 (96.4)	259 (78.3)
2012	365 (100.0)	254 (69.6)	365 (100.0)	348 (95.3)	347 (95.1)	305 (83.4)
2013	436 (100.0)	278 (63.8)	435 (99.7)	405 (92.9)	413 (71.7)	356 (81.7)
2014, Q1	110 (100.0)	73 (66.4)	109 (99.1)	105 (95.5)	101 (91.8)	93 (84.6)

MRSA Blood Isolates (n = 458)						
Year	Gentamicin ^a	Erythromycin	Rifampin	Tetracycline ^b	Ciprofloxacin	Clindamycin
	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)
2006	82 (100.0)	8 (9.8)	77 (93.9)	82 (100.0)	32 (39.0)	38 (46.3)
2007	67 (100.0)	9 (13.4)	66 (98.5)	67 (100.0)	23 (34.3)	33 (49.3)
2008	45 (100.0)	5 (11.1)	44 (97.8)	45 (100.0)	22 (48.9)	26 (57.8)
2009	62 (100.0)	7 (11.3)	62 (100.0)	62 (100.0)	26 (41.9)	33 (53.2)
2010	45 (100.0)	0 (0.0)	43 (95.6)	45 (100.0)	19 (41.9)	17 (37.8)
2011	41 (100.0)	2 (4.9)	39 (95.1)	40 (97.6)	27 (65.9)	21 (51.2)
2012	53 (100.0)	6 (11.3)	52 (98.1)	44 (83.0)	17 (32.8)	28 (52.8)
2013	44 (100.0)	6 (13.6)	43 (97.7)	39 (88.6)	18 (40.9)	25 (56.8)
2014, Q1	19 (100.0)	1 (5.3)	18 (94.7)	13 (68.4)	5 (26.3)	6 (31.6)

TABLE 3. *Continued*

MSSA Blood Isolates (n = 578)						
Year	Gentamicin ^a	Erythromycin	Rifampin	Tetracycline ^b	Ciprofloxacin	Clindamycin
	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)	No. (% susceptible)
2006	92 (100.0)	67 (72.8)	92 (100.0)	91 (98.9)	86 (92.4)	85 (92.4)
2007	79 (100.0)	59 (74.7)	79 (100.0)	79 (100.0)	74 (93.7)	68 (86.1)
2008	71 (100.0)	51 (71.8)	70 (98.6)	71 (100.0)	60 (84.5)	57 (80.3)
2009	55 (100.0)	48 (87.3)	55 (100.0)	55 (100.0)	52 (94.6)	50 (90.9)
2010	62 (100.0)	44 (71.0)	62 (100.0)	62 (100.0)	57 (91.9)	47 (75.8)
2011	59 (100.0)	44 (74.6)	59 (100.0)	58 (98.3)	58 (98.3)	50 (84.8)
2012	65 (100.0)	51 (78.5)	65 (100.0)	62 (95.4)	62 (95.4)	53 (81.5)
2013	77 (100.0)	56 (72.7)	77 (100.0)	74 (96.1)	71 (92.2)	65 (84.4)
2014, Q1	18 (100.0)	12 (66.7)	18 (100.0)	17 (94.4)	17 (94.4)	14 (77.8)

NOTE. MSSA, methicillin-susceptible *Staphylococcus aureus*; MRSA, methicillin-resistant *Staphylococcus aureus*; Q1, first quarter of the year; SSTI, skin and soft tissue infection.

^aNo resistant isolates were observed for gentamicin.

^bSignificant decrease ($P < 0.05$).